JP Morgan Chase’s Candel Therapeutics CADL Stock Holding History
Bought
Maintained
Sold
Other funds holding CADL
RI
ACA
PCM
SVCM
JP Morgan Chase's CADL Position: Q2 2026 in Review
JP Morgan Chase increased its Candel Therapeutics (CADL) stake by 31% in Q2 2026, buying an estimated $58.7K and bringing the position to 32,634 shares worth $338K. The position accounts for ﹤0.01% of the portfolio, ranked #5325.
JP Morgan Chase first reported a position in CADL in Q4 2021 and has held it in 19 quarters since. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.
- JP Morgan Chase held 32,634 shares of Candel Therapeutics worth $338K as of Q2 2026.
- JP Morgan Chase bought 7,771 Candel Therapeutics shares in Q2 2026, an estimated $58.7K.
- Candel Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #5325 holding.
- JP Morgan Chase first reported a position in Candel Therapeutics in Q4 2021 and has held it in 19 quarters since.
- 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.